Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity
- PMID: 2364440
- DOI: 10.1016/0008-8749(90)90201-2
Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity
Abstract
The MCA 102 sarcoma has been defined by a variety of immunologic studies as a tumor lacking intrinsic immunogenicity. Nevertheless, we have recently demonstrated the feasibility of generating therapeutically effective lymphocytes for adoptive immunotherapy of this tumor. Procedures to achieve this required in vivo priming of syngeneic mice to elicit preeffector cells followed by in vitro sensitization (IVS) with tumor cells in the presence of IL-2. By selective depletion of T cell subsets in vivo, we identified the involvement of both CD4+ (L3T4+) and CD8+ (Lyt-2+) T cells in mediating tumor regression. The CD4+ cells exerted their helper function via the secretion of IL-2 because antitumor effects abrogated by depletion of CD4+ cells could be reconstituted by exogenous IL-2. In order to elicit preeffector cells with reactivity against the MCA 102 tumor, we found that in vivo sensitization could be accomplished with either the MCA 102 or MCA 106 tumor but not with the MCA 101 or MCA 105 tumor. Analysis of specificity of tumor stimulation during IVS of MCA 102 tumor-primed preeffector cells demonstrated cross-reactivity between not only the MCA 102 and MCA 106 tumors but also the MCA 105 tumor whereas the MCA 101 tumor was ineffective. In adoptive immunotherapy, transfer of IVS cells generated from MCA 102 tumor-primed and stimulated lymph node cells was able to mediate reductions of pulmonary metastases established from the MCA 102, MCA 105, and MCA 106 tumors but not from the MCA 101 tumor. We conclude that regression of the MCA 102 tumor is probably mediated through T cell recognition of a set of common tumor-associated Ag shared by several other syngeneic tumors. Immunologically, the tumor-associated Ag are characteristically different from classical tumor-specific transplantation Ag (TSTA) because immunity to TSTA on the MCA 105 or MCA 106 tumor does not cross-react with the MCA 102 tumor. Thus, this study demonstrates that Ag other than TSTA on chemically induced tumors can serve as target molecules for T cell-mediated adoptive immunotherapy.
Similar articles
-
Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.J Immunol. 1988 Aug 1;141(3):1047-53. J Immunol. 1988. PMID: 3260908
-
Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.Cancer Res. 1990 Jul 15;50(14):4371-6. Cancer Res. 1990. PMID: 2114215
-
Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.J Immunol. 1991 Jul 15;147(2):729-37. J Immunol. 1991. PMID: 1830072
-
Modulation of antitumor immunity--immunobiologic approaches.Springer Semin Immunopathol. 1982;5(2):193-220. doi: 10.1007/BF00199796. Springer Semin Immunopathol. 1982. PMID: 6293113 Review. No abstract available.
-
Adoptive immunotherapy of cancer with immune and activated lymphocytes: experimental and clinical studies.Ric Clin Lab. 1986 Jan-Mar;16(1):1-20. doi: 10.1007/BF02886719. Ric Clin Lab. 1986. PMID: 2874605 Review.
Cited by
-
Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.J Neurooncol. 1996 Feb;27(2):179-89. doi: 10.1007/BF00177482. J Neurooncol. 1996. PMID: 8699241 Clinical Trial.
-
Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo.J Exp Med. 1994 Jan 1;179(1):31-42. doi: 10.1084/jem.179.1.31. J Exp Med. 1994. PMID: 8270874 Free PMC article.
-
Activation of T lymphocytes for the adoptive immunotherapy of cancer.Ann Surg Oncol. 1994 Jul;1(4):296-306. doi: 10.1007/BF02303568. Ann Surg Oncol. 1994. PMID: 7850528 Review.
-
Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours.Cancer Immunol Immunother. 1991;34(1):53-62. doi: 10.1007/BF01741325. Cancer Immunol Immunother. 1991. PMID: 1760812 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials